Ivosidenib

Drug Profile

Ivosidenib

Alternative Names: AG 120

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cholangiocarcinoma
  • Phase I/II Acute myeloid leukaemia
  • Phase I Glioma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 17 Apr 2017 Chemical structure information added
  • 02 Apr 2017 Agios Pharmaceutical initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT03071770)
  • 09 Mar 2017 Agios Pharmaceutical plans a phase I trial in Healthy volunteers in USA (NCT03071770)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top